<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-662
Date of Submission: 2024-09-16

This report was submitted by a Other Healthcare Professional from Strickland, Palmer and Hall Medical Center concerning patient ANON-PX-3764. The subject is a 40-year-old other with a significant medical history including migraines, atrial fibrillation, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intravenous route at a dosage of 302mg, initiated on 2024-08-26 for Hypercholesterolemia with the course ongoing; Warfarin (Anticoagulant) administered via the Intramuscular route at a dosage of 194mg, initiated on 2024-08-26 for Thromboembolism prevention with the course ongoing.

On approximately 2024-09-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Dizziness. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2024-662
report_date: '2024-09-16'
patient_details:
  patient_id: ANON-PX-3764
  gender: Other
  relevant_history:
  - migraines
  - atrial fibrillation
  - seasonal allergies
  age_at_reaction: 40
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 302mg
  route_of_administration: Intravenous
  start_date: '2024-08-26'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
- drug_name: Warfarin
  dosage: 194mg
  route_of_administration: Intramuscular
  start_date: '2024-08-26'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2024-09-12'
  severity: Severe
  outcome: Not Recovered
  intervention_required: true
- symptom_name: Dizziness
  onset_date: '2024-09-12'
  severity: Severe
  outcome: Recovering
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 8
reporting_facility: Strickland, Palmer and Hall Medical Center
reporter_type: Other Healthcare Professional
